Open Angle Glaucoma Clinical Trial
Official title:
A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Pattern Recorded With Triggerfish® in Patients With Open Angle Glaucoma Before and After DSCI
A prospective, open label study to assess the 24-hour intraocular pressure pattern recorded with SENSIMED Triggerfish® in patients with open angle glaucoma before and after deep sclerectomy with collagen implant
This is a prospective, open label study to assess the 24-hour IOP pattern recorded by SENSIMED Triggerfish® in Open Angle Glaucoma (OAG) patients before and after deep sclerectomy with collagen implant (DSCI). After having signed and dated the patient informed consent form, patients will undergo an initial ophthalmic examination. The contact lens sensor (CLS) SENSIMED Triggerfish® will be placed on the study eye as selected for DSCI, for a baseline 24-hour IOP pattern recording session (S1), within 7 days preceding the surgical procedure. Patients will remain ambulatory and will be encouraged to follow a schedule as close to his/her usual lifestyle as possible. A patient diary will be distributed for the capture of patient activities during the IOP pattern recording. Upon completion of S1, the contact lens sensor (CLS) SENSIMED Triggerfish® will be removed and a final ophthalmic examination will be conducted. The patient diary will be collected and concomitant medication will be reported. The surgery will be scheduled within 2 days following S1. Unless contraindicated (e.g. large filtering bleb precluding placement of the contact lens sensor (CLS) SENSIMED Triggerfish®), patients will undergo a second 24-hour contact lens sensor (CLS) SENSIMED Triggerfish® IOP pattern recording session (S2) on the study eye 3 months after the surgical procedure. S2 will start at the same time of day ± 30 min as S1, preferably at a time that allows for sufficient recording of the wake-to-sleep and the sleep-to-wake phases. Prior to S2 and upon completion of thereof, ophthalmic examinations will be conducted and patient diary will be collected. In addition, any specifics regarding the DSCI and medication will be reported. A visual field (VF) assessment will also be performed to evaluate the changes after deep sclerectomy with collagen implant. Patients will undergo a third 24-hour SENSIMED Triggerfish® IOP pattern recording session (S3) on the study eye 12 months after the surgical procedure. S3 will start at the same time of day ± 30 min as S2, preferably at a time that allows for sufficient recording of the wake-to-sleep and the sleep-to-wake phases. Prior to S3 and upon completion of thereof, ophthalmic examinations will be conducted and patient diary will be collected. In addition, any specifics regarding the deep sclerectomy with collagen implant (DSCI) and medication will be reported. A visual field assessment will also be performed to evaluate the changes after deep sclerectomy with collagen implant (DSCI).This concludes the study for the patients. Hence, the overall study duration for the patient is limited to 13 months. The study has been planned to recruit at least 40 eligible patients within 11 months from initiation. Hence the overall study duration from the first patient accrued into the study until last patient out equates to about 24 months or less. Allowing for a database lock within 4 weeks of study completion, a preliminary statistical report on the primary efficacy endpoint is foreseen within 2 weeks thereafter. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Terminated |
NCT03611530 -
CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma
|
N/A | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Not yet recruiting |
NCT02868502 -
Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma
|
N/A | |
Completed |
NCT02272569 -
STARflo European Safety and Efficacy Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT00941525 -
Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure
|
Phase 4 | |
Completed |
NCT00539526 -
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
|
Phase 4 | |
Completed |
NCT00121147 -
Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan
|
N/A | |
Active, not recruiting |
NCT05035394 -
Swedish Microinvasive Glaucoma Surgery Study (SMIGS)
|
N/A | |
Completed |
NCT03450629 -
Evaluation of Safety and Efficacy of PDP-716
|
Phase 3 | |
Active, not recruiting |
NCT06061718 -
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
|
Phase 3 | |
Recruiting |
NCT05241938 -
PSLT Compared to Prostaglandin Analogue Eye Drops
|
N/A | |
Completed |
NCT01342406 -
Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics
|
||
Completed |
NCT02250612 -
SYL040012, Treatment for Open Angle Glaucoma
|
Phase 2 | |
Terminated |
NCT01983579 -
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
|
Phase 4 | |
Completed |
NCT01937299 -
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
|
Phase 4 | |
Completed |
NCT01937312 -
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
|
Phase 4 | |
Completed |
NCT01229982 -
A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
|
Phase 2 |